Oxford BioMedica PLC (OXB.L) To Participate At Piper Jaffray Genomerx Symposium In New York On 23 June 2014
6/20/2014 9:00:09 AM
Oxford, UK – 20 June 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it will attend Piper Jaffray’s GenomeRx Symposium on Monday, June 23, 2014 at The Yale Club, New York.
Oxford BioMedica’s Chief Executive Officer, John Dawson, and Kyriacos Mitrophanous PhD, Head of Research, will take part in a panel discussion entitled “Ophthalmology: Seeing The Future of Gene Therapy Clearly” detailing trends for gene therapy in ophthalmology from 12:45 – 1:40 pm (UTC).
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Mary-Jane Elliott/Emma Thompson/Matthew Neal
Consilium Strategic Communications
Tel: +44 (0)20 3709 5700
About Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.
Help employers find you! Check out all the jobs and post your resume.